When someone is living with severe depression, waiting weeks for relief can feel impossible.
A newly published systematic review and meta-analysis in JAMA Psychiatry provides some of the strongest evidence to date that physician-administered intravenous (IV) ketamine can rapidly reduce both depressive symptoms and suicidal thoughts in people experiencing a major depressive episode.
Why This Study Matters
Individual studies have shown promising results with IV ketamine for years. This new publication is different because it combined results from 26 randomized clinical trials involving 1,166 patients, making it one of the largest and most comprehensive analyses available.
By reviewing many high-quality studies together, researchers were able to better understand both the effectiveness and safety of IV ketamine treatment.
The Results Were Remarkable
Researchers found that a single IV ketamine infusion significantly reduced depressive symptoms:
- Within 4 hours
- At 24 hours
- At 3 days
- At 1 week
Repeated ketamine infusions also continued to show meaningful improvements by the end of treatment.
For individuals experiencing suicidal thoughts, the findings were equally encouraging.
Participants experienced significant reductions in suicidal symptoms:
- Within 24 hours after a single infusion
- Continuing for up to one month in some studies
- Following repeated infusion protocols as well
Speed Matters
Traditional antidepressants are effective for many people, but they often require four to eight weeks before patients notice significant improvement.
IV ketamine works differently.
Rather than waiting weeks, many patients begin experiencing symptom relief within hours, making it an important option for individuals with treatment-resistant depression or those in acute emotional distress.
What About Safety?
The researchers also examined safety across all 26 clinical trials.
They found that:
- Serious adverse events were not related to ketamine treatment
- The most common side effects—including headache, nausea, dizziness, and temporary dissociation—were generally mild, short-lived, and resolved during treatment.
Like any medical treatment, IV ketamine should only be administered after a thorough medical evaluation and under physician supervision.
Important Limitations
The study also highlights what researchers still don’t know.
While evidence strongly supports ketamine’s rapid benefits during the acute phase of depression, researchers note that long-term outcomes require additional study.
That is why ongoing physician oversight, personalized treatment planning, and follow-up care remain essential.
What This Means for Patients
Depression can make it difficult to believe that things can improve.
Research like this offers hope—not because ketamine is a cure, but because it provides another evidence-based option for people who haven’t found relief with traditional treatments.
At Mindset Integrative Ketamine Care, physician-administered IV ketamine is provided in a safe, carefully monitored medical environment. Every treatment begins with a comprehensive evaluation to determine whether ketamine therapy is appropriate for each individual.
If you or someone you love has struggled with treatment-resistant depression or persistent suicidal thoughts, know that new options exist—and they continue to be supported by growing scientific evidence.
You don’t have to navigate depression alone.
